Literature DB >> 1610738

Use of myxalin for improving vascular graft healing: evaluation of biocompatibility in rats.

A Akoum1, Y Marois, R Roy, M King, R Guidoin, M Sigot, M F Sigot-Luizard.   

Abstract

Myxalin is a glycopeptide extracted recently from a gram-negative bacterium. It has blood anticoagulant properties and can enhance endothelial cell growth. With the ultimate objective of using this bioactive molecule to promote vascular graft healing, this study assessed its biocompatibility in vivo by comparing the cellular and immunological responses of gelatin-coated knitted polyester grafts with and without myxalin following implantation in the peritoneal cavity of rats for prescheduled periods of 3 days and 1, 2, and 4 weeks. A nongelatin-coated virgin polyester graft was included as the reference material. The biological response to gelatin alone was characterized by a slower rate of cellular infiltration into the implant, reduced collagen synthesis, and higher levels of acid phosphatase and esterase activity in the surrounding tissue. The addition of myxalin to this coating resulted in a significant reduction of hydrolase secretion in the tissue surrounding the implant and an enhancement of cellular ingrowth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1610738     DOI: 10.3109/08941939209012429

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  2 in total

1.  Precoating of alloplastic materials with living human fibroblasts--a feasibility study.

Authors:  M Kapischke; K Prinz; J Tepel; J Tensfeldt; T Schulz
Journal:  Surg Endosc       Date:  2005-05-04       Impact factor: 4.584

2.  Interaction of human plasma proteins with thin gelatin-based hydrogel films: a QCM-D and ToF-SIMS study.

Authors:  Sina M S Schönwälder; Florence Bally; Lars Heinke; Carlos Azucena; Özgül D Bulut; Stefan Heißler; Frank Kirschhöfer; Tim P Gebauer; Axel T Neffe; Andreas Lendlein; Gerald Brenner-Weiß; Jörg Lahann; Alexander Welle; Jörg Overhage; Christof Wöll
Journal:  Biomacromolecules       Date:  2014-07-02       Impact factor: 6.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.